News from hoth therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 06, 2023, 08:02 ET Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that HT-ALZ a therapeutic in development for the ...

May 12, 2023, 08:38 ET Hoth Therapeutics and Algorithm Sciences Terminate Letter of Intent to Merge

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that they have entered into a mutual agreement...

Apr 26, 2023, 08:18 ET Hoth Therapeutics and Algorithm Sciences Execute Letter of Intent to Merge

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced it has signed a Letter of Intent to merge with...

Mar 08, 2023, 09:09 ET Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the activation of Washington University School...

Feb 16, 2023, 08:35 ET Hoth Therapeutics Retains ShareIntel to Investigate Illegal Naked Shorting Activity

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a service agreement with ...

Feb 08, 2023, 08:43 ET Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced proof-of-concept data generated using cognitive...

Jan 25, 2023, 08:27 ET Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has selected 3 of its clinical sites for ...

Jan 03, 2023, 16:38 ET Hoth Therapeutics Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth"), a patient-focused biopharmaceutical company, today announced the closing of its...

Dec 29, 2022, 20:00 ET Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement...

Dec 29, 2022, 08:45 ET Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) ...

Dec 01, 2022, 10:46 ET Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it submitted an Investigational New Drug...

Nov 09, 2022, 12:38 ET Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it received written notice from the NASDAQ...

Oct 31, 2022, 09:57 ET HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced positive data for BioLexa, its investigational...

Oct 24, 2022, 16:15 ET Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will effect a 1-for-25 reverse split of...

Sep 20, 2022, 09:05 ET Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with Altasciences, a...

Sep 06, 2022, 08:21 ET Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and Allergy Disorders

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced development updates for its novel asthma and...

Aug 12, 2022, 13:48 ET Hoth Therapeutics Announces Pipeline Presentation at the 2022 Sidoti Investor Conference

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today announced the company will be presenting...

Jul 12, 2022, 10:26 ET Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced proof-of-concept data generated using cognitive...

Jun 29, 2022, 13:25 ET Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("Hoth" or the "Company") today announced that the Company received confirmation from the Listing...

Jun 21, 2022, 12:30 ET Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has received approval by the Bellberry Human...

Jun 15, 2022, 12:30 ET Hoth Announces Adjournment of Annual Meeting of Shareholders Until June 23, 2022

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that its Annual Meeting of Shareholders...

Jun 09, 2022, 08:18 ET Hoth Therapeutics Announces Extension of Washington University Alzheimer's Mouse Model Study with Alzheimer's Therapeutic HT-ALZ

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into an extension of its...

May 03, 2022, 08:09 ET Hoth Therapeutics Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the preliminary findings from Hoth's randomized, ...

Apr 19, 2022, 10:29 ET Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain Injury

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the company is adding a new asset to its...

Apr 14, 2022, 13:02 ET Hoth Therapeutics, Inc. Announces Closing of $7.0 Million Underwritten Public Offering Priced At-The-Market

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the closing of its previously announced...